A phase III trial of higher dose of Qapzola in patients with non-muscle invasive bladder cancer
Phase of Trial: Phase III
Latest Information Update: 02 May 2017
At a glance
- Drugs Apaziquone (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 02 May 2017 According to a Spectrum Pharmaceuticals media release, this trial is expected to enrolling patients in the third quarter of 2017.
- 14 Mar 2017 New trial record
- 08 Mar 2017 According to a Spectrum Pharmaceuticals media release, the company has received a new Special Protocol Agreement (SPA) on this trial from the US FDA and the trial has been designed based on recommendations from the FDA.